Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25193264 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25515343 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25193261 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25188735 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25202190 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25516141 | 0.80 | CNR2 (0.36) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25516127 | 0.80 | CNR2 (0.36) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25516130 | 0.80 | CNR2 (0.36) | SMN1; SMN2MAPTTP53LMNAMEN1 | |
| SCHEMBL25184598 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTTP53MEN1KMT2A | |
| SCHEMBL25265105 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034105-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023081899-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034105-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | DBH, PNMT, MBTD1 | SMN1; SMN2 54/4885MAPT 863/4885TP53 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.